Oblique Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
17
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$2.74M
- Investors
-
9
Oblique Therapeutics General Information
Description
Developer of antibody-based drugs designed to treat advanced and metastatic cancer. The company specializes in the research and development of a solid portfolio based on asset generation through advanced antibody technology for severe diseases with a large unmet medical need, focusing on pain and advanced cancer, enabling scientists and researchers to generate novel medicines against any disease-modifying human protein target.
Contact Information
Website
www.obliquet.comCorporate Office
- Arvid Wallgrens Backe 20
- 413 46 Gothenburg
- Sweden
Corporate Office
- Arvid Wallgrens Backe 20
- 413 46 Gothenburg
- Sweden
Oblique Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 08-Jul-2022 | $2.74M | Completed | Product Development | ||
| 6. Later Stage VC | 18-Nov-2020 | Completed | Product Development | |||
| 5. Grant | 19-Dec-2017 | Completed | Product Development | |||
| 4. Early Stage VC | 01-Dec-2016 | Completed | Product Development | |||
| 3. Grant | 16-Nov-2016 | Completed | Product Development | |||
| 2. Early Stage VC | 11-Dec-2015 | $1.27M | $1.27M | Completed | Product Development | |
| 1. Accelerator/Incubator | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Oblique Therapeutics Patents
Oblique Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023017149-A1 | Thioredoxin 1 antibodies | Inactive | 13-Aug-2021 | ||
| GB-202108663-D0 | Trpv1 antibodies | Inactive | 17-Jun-2021 | ||
| WO-2022219152-A1 | Kras antibodies | Inactive | 16-Apr-2021 | ||
| GB-202101780-D0 | Epitopes and antibodies | Inactive | 09-Feb-2021 | ||
| GB-202019522-D0 | Epitopes and antibodies | Inactive | 10-Dec-2020 | C07K16/28 |
Oblique Therapeutics Signals
Oblique Therapeutics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alsteron | Family Office | Minority | ||
| Granitor | Venture Capital | Minority | ||
| Jinderman & Partners | Venture Capital | Minority | ||
| Sunstone Life Science Ventures | Venture Capital | Minority | ||
| Angel (individual) | Minority |
Oblique Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Cinda Pharma | Goteborg, Sweden | 2016 |
Oblique Therapeutics FAQs
-
When was Oblique Therapeutics founded?
Oblique Therapeutics was founded in 2015.
-
Where is Oblique Therapeutics headquartered?
Oblique Therapeutics is headquartered in Gothenburg, Sweden.
-
What is the size of Oblique Therapeutics?
Oblique Therapeutics has 17 total employees.
-
What industry is Oblique Therapeutics in?
Oblique Therapeutics’s primary industry is Biotechnology.
-
Is Oblique Therapeutics a private or public company?
Oblique Therapeutics is a Private company.
-
What is Oblique Therapeutics’s current revenue?
The current revenue for Oblique Therapeutics is .
-
How much funding has Oblique Therapeutics raised over time?
Oblique Therapeutics has raised $15.2M.
-
Who are Oblique Therapeutics’s investors?
Alsteron, Granitor, Jinderman & Partners, Sunstone Life Science Ventures, and are 5 of 9 investors who have invested in Oblique Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process